We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NIH Investigators Blast Xigris Guidelines as a Marketing Ploy
NIH Investigators Blast Xigris Guidelines as a Marketing Ploy
October 20, 2006
Eli Lilly developed fraudulent practice guidelines based on limited data, input from researchers with financial conflicts and the work of industry front groups to increase sales of its sepsis treatment Xigris, according to three NIH investigators.